Rash, Dose Modifications, and Conclusions at Extended Follow-Up

Luis E. Raez, MD, of Miami Cancer Institute, reports that with extended COPERNICUS follow-up, rash in the first 4 months of subcutaneous amivantamab plus lazertinib was lower than in MARIPOSA, similar across age groups, and less often grade 2 or higher, with lower cumulative incidence by 1 year. Wade T. Iams, MD, of Tennessee Oncology, notes that most treatment-emergent adverse events were grade 1 or 2 with no new safety signals, grade 3 or higher dermatitis acneiform occurred in 4% of participants, and 8% discontinued both drugs because of adverse events beginning in the first 4 months. Dose reductions occurred in 20% and interruptions in 46%. Dr Raez notes that temporarily holding amivantamab does not appear to erase its benefit. In closing, he says prophylaxis reduced skin toxicity, thrombosis, and administration-related reactions, with discontinuations from these events by 1 year markedly lower than the 9% in MARIPOSA.